Crystal of a kinase-ligand complex and methods of use

Details Crystal of a kinase-ligand complex and methods of use Crystal of a kinase-ligand complex and methods of use

2001-05-21

2003-07-08

Leary, Louise N. (Department: 1627)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving transferase

C435S004000, C530S350000

Reexamination Certificate

active

06589758

ABSTRACT:

BACKGROUND OF THE INVENTION
The invention relates to the three-dimensional structure of a crystal of a kinase enzyme complexed with a ligand. The three-dimensional structure of a protein kinase-ligand complex is disclosed. The invention also relates to methods of preparing such crystals. Kinase-ligand crystal structures wherein the ligand is an inhibitor molecule are useful for providing structural information that may be integrated into drug screening and drug design processes. Thus, the invention also relates to methods of using the crystal structure of kinase enzyme-ligand complexes for identifying, designing, selecting, or testing inhibitors of kinase enzymes, such inhibitors being useful as therapeutics for the treatment or modulation of i) diseases; ii) disease symptoms; or iii) the effect of other physiological events mediated by kinases; having one or more kinase enzymes involved in their pathology.
T-cell activation is a complex process that results from the integrated activation of multiple signal transduction pathways [1-3]. One of the earliest T-cell signaling events observed upon T-cell receptor (TCR)-ligand engagement is the CD4/CD8-dependent activation of lymphocyte kinase (Lck), a member of the non-receptor Src family of tyrosine kinases [4-8]. Lck phosphorylates and activates a number of substrates necessary for TCR signaling [9]. Perhaps the best understood activity of Lck is the phosphorylation of immunoreceptor tyrosine-based activation motifs (ITAMs) in the TCR &zgr;-subunit [4, 6, 9]. The extent of &zgr;-chain ITAM phosphorylation dictates the threshold for ligand-mediated TCR signaling and T-cell activation [10, 11]. Phosphorylated ITAMs serve as high affinity docking sites for the recruitment of additional signaling factors, particularly the Syk family tyrosine kinase ZAP-70 [12, 13]. Dual phosphorylation of tyrosines in the ITAMs by Lck is required for the binding of tandem ZAP-70 Src homology-2 (SH2) domains [14-16]. Co-localization of ZAP-70 and Lck to the TCR-&zgr; subunit-CD4/8 complex facilitates the Lck-mediated activation of ZAP-70 and subsequent ZAP-70 autophosphorylation [17-21]. Activated Lck and ZAP-70 perpetuate the TCR signaling cascade by providing additional docking sites for other SH2 containing kinases (including Fyn, Syk and Itk), adaptor proteins (including SLP-76, SHC, LAT, FyB and Grap), and transducing elements (including PLC&ggr;, PI3-kinase and Rac/Rho) [2, 3, 22]. Biochemical information is then transmitted down multiple signaling pathways, including the Ras/mitogen-activated protein kinase pathway, the phosphatidylinositol pathway, and the Rho/Rac pathway [2]. Among other effects, TCR signaling up-regulates transcription and translation of IL-2 and IL-2 receptors which are prerequisites for T-cell proliferation.
Genetic studies have demonstrated that Lck expression is restricted to lymphocytes. Loss of Lck expression in human Jurkat T-cells results in a loss of signaling in response to TCR ligation [23, 24]. In addition, inactivation of the Lck gene, or expression of dominant negative transgenes in mice, results in early arrest of thymocyte maturation [25-27]. These and other biochemical studies have implicated Lck as an essential early mediator of the TCR signaling pathway. Lck therefore represents an attractive target for therapeutic intervention in T-cell mediated disorders such as autoimmune diseases and transplant rejection.
Lck is a modular protein consisting of a C-terminal catalytic domain, a single Src homology-2 (SH2) and a Src homology-3 (SH3) domain, and a unique N-terminal region. The N-terminal region is involved in anchoring Lck to CD4/8 through Zn
2+
coordination with conserved cysteine residues present in both proteins [28, 29]. The activity of Lck is regulated by autophosphorylation of Tyr-394 located in the catalytic domain activation loop [30] and by the phosphorylation of Tyr-505 by C-terminal Src kinase (Csk) [31-33]. Further understanding of the regulation of Lck has been provided by the crystal structures of two other Src family protein kinases, c-Src and Hck [34-36]. From these structures it can be delineated that the SH2 and SH3 domains function in part to negatively regulate Lck activity by forming intramolecular contacts that stabilize the catalytic domain in an inactive conformation [37]. The SH2 domain binds to phosphorylated Tyr-505 and the SH3 domain associates with a proline containing motif in a hinge region connecting the SH2 and catalytic domains [34-36]. Release of these intramolecular regulatory constraints by dephosphorylation of Tyr-505 [38] and/or the presence of competing SH3/SH2 ligands [39] results in the autophosphorylation of Tyr-394 in the activation loop and a catalytically active kinase [19]. A structural basis for Lck activation has been previously elucidated from the crystal structure of an autophosphorylated Lck catalytic domain [40].
Protein kinases have been implicated as potential targets for a variety of clinical applications. The identification of molecules, such as inhibitors, that bind to kinase enzymes, affect kinase activity and thereby influence pathological processes, is valuable for investigating potential therapeutics for disease, or disease symptoms, that are mediated by kinase enzymes. Such identification has been attempted using methods such as the screening of large numbers of random libraries of natural and/or synthetic compounds, hoping that some number of random compounds will demonstrate the desired biological activity. This method is inefficient in that it typically results in a small number of “hits” and it is constrained by the limitations imposed in actually screening large numbers of compounds in laboratory assays. An improved method of such identification is structure-based drug design (“SBDD”). SBDD comprises a number of integrated components, including, structural information (e.g., spectroscopic data such as X-ray or magnetic reasonance information, relating to enzyme structure and/or conformation, enzyme-ligand interactions, etc.), computer modeling, medicinal chemistry, and biological testing (both in vitro and in vivo). These components, each alone and in combination, are useful for accelerating the drug discovery process, for gaining insight into disease and disease processes, and for providing a more efficient method for identifying drug candidates.
Efforts to understand the molecular constraints necessary to achieve inhibitor potency and selectivity have been aided by an increasing number of crystal structures of different protein kinases complexed with ATP-competitive inhibitors. One such inhibitor is staurosporine, an alkaloid that has been previously shown to inhibit a broad range of tyrosine and serine/threonine kinases with nanomolar potency [41]. Crystal structures of staurosporine bound to the serine/threonine kinases protein kinase A (PKA) and the cyclin-dependent kinase 2 (CDK2) elucidated the binding mode of this inhibitor to protein kinases [42, 43] (reviewed in [44]). A similar binding mode has been reported in a recently solved structure of the tyrosine kinase Csk in complex with staurosporine [45]. Described herein are crystal structures of Lck complexed with staurosporine obtained from both soaking and co-crystallization experiments. Comparison of these two complexes and those previously reported further elucidates the structural basis for the high potency and poor selectivity of this inhibitor.
To date, the three-dimensional structures of Hck/AMP-PNP and Hck/Quercetin complexes have been reported, however, these ligands are not src-selective ligands. The three-dimensional structure of c-Src (apo form) has been elucidated, however, this structure lacks a ligand bound to the enzyme and therefor lacks critical information regarding the interaction of a ligand with t

Affiliated with

Also associated with

Rating

Crystal of a kinase-ligand complex and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Crystal of a kinase-ligand complex and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystal of a kinase-ligand complex and methods of use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3078952